Jain Ayushi, Sharma Pooja, N Sivakumar, Sharma Kriti, Gupta Shalini
Dept of Oral Pathology, Microbiology and Forensic Odontology, King George's Medical University, Lucknow, 226003 UP India.
Dept of Oral Pathology, Microbiology and Forensic Odontology, All India Institute of Medical Sciences, New Delhi, 110029 India.
Indian J Otolaryngol Head Neck Surg. 2024 Feb;76(1):1178-1182. doi: 10.1007/s12070-023-04203-4. Epub 2023 Sep 7.
Brown tumor represents a terminal stage of bone remodeling process due to an imbalance between osteoclastic and osteoblastic activity. It represents a reparative cellular process, rather than a neoplastic process mostly associated with primary or secondary hyperparathyroidism. Although parathyroidectomy is the first treatment of choice for brown tumors, several cases don't resolve even after normalization of parathyroid hormone levels which leads to surgical intervention. Therefore, to avoid multiple bone surgeries in the same patient, it is crucial to have a conservative approach like targeted therapy which could block certain molecules involved in bone resorption. In this string, we have recognized and quantified three molecules namely sclerostin, MCP-1 and CD73 in brown tumors and correlated their expression with bone resorption pathogenesis and potential therapeutic approach.
棕色瘤代表由于破骨细胞和成骨细胞活性失衡导致的骨重塑过程的终末期。它代表一种修复性细胞过程，而非主要与原发性或继发性甲状旁腺功能亢进相关的肿瘤性过程。尽管甲状旁腺切除术是棕色瘤的首选治疗方法，但即使甲状旁腺激素水平恢复正常，仍有一些病例无法缓解，这就需要进行手术干预。因此，为避免同一患者进行多次骨手术，采取如靶向治疗这样的保守方法至关重要，靶向治疗可以阻断参与骨吸收的某些分子。在此研究中，我们已识别并量化了棕色瘤中的三种分子，即骨硬化蛋白、单核细胞趋化蛋白-1和CD73，并将它们的表达与骨吸收发病机制及潜在治疗方法相关联。
